Is BRCA Mutation Testing Cost Effective for Early Stage Breast Cancer Patients Compared to Routine Clinical Surveillance? The Case of an Upper Middle-Income Country in Asia.
Ka Keat LimSook Yee YoonNur Aishah Mohd TaibFatiha Hana ShabaruddinMaznah DahluiYin Ling WooMeow Keong ThongSoo Hwang TeoNathorn ChaiyakunaprukPublished in: Applied health economics and health policy (2019)
Offering BRCA mutation testing to early-stage breast cancer patients identified using a locally-validated risk-assessment tool may be cost effective compared to RCS in Malaysia.